Subject(s)
Betacoronavirus/pathogenicity , Communicable Disease Control/standards , Coronavirus Infections/prevention & control , Dermatology/standards , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , COVID-19 , Communicable Disease Control/instrumentation , Communicable Disease Control/trends , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Coronavirus Infections/virology , Dermatitis, Contact/etiology , Dermatitis, Contact/prevention & control , Dermatitis, Occupational/etiology , Dermatitis, Occupational/prevention & control , Dermatologists/education , Dermatologists/standards , Dermatology/education , Dermatology/trends , Education, Medical/standards , Education, Medical/trends , Hand Hygiene/standards , Humans , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Infectious Disease Transmission, Professional-to-Patient/prevention & control , Nepal/epidemiology , Personal Protective Equipment/adverse effects , Personal Protective Equipment/standards , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Pneumonia, Viral/virology , SARS-CoV-2Subject(s)
Clinical Laboratory Techniques , Coronavirus Infections/complications , Dermatologists/standards , Pneumonia, Viral/complications , Severity of Illness Index , Skin Diseases, Viral/virology , COVID-19 , COVID-19 Testing , Coronavirus Infections/diagnosis , Dermatology , Humans , Lung/pathology , Pandemics , Skin/pathology , Skin Diseases, Viral/diagnosisABSTRACT
Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in coronavirus disease 2019 (COVID-19) are scarce. This article reviews and offers guidance based on currently available safety data and the most recent COVID-19 outcome data in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasizes a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic.
Subject(s)
Coronavirus Infections/prevention & control , Dermatology/standards , Immunosuppression Therapy/standards , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Practice Guidelines as Topic , Skin Diseases/therapy , Advisory Committees/standards , Betacoronavirus/immunology , Betacoronavirus/pathogenicity , COVID-19 , Clinical Decision-Making , Coronavirus Infections/epidemiology , Coronavirus Infections/immunology , Coronavirus Infections/virology , Decision Making, Shared , Dermatologists/standards , Dermatology/methods , Disease Susceptibility/immunology , Hospitalists/standards , Humans , Immunosuppression Therapy/adverse effects , Immunosuppression Therapy/methods , Interdisciplinary Communication , Pneumonia, Viral/epidemiology , Pneumonia, Viral/immunology , Pneumonia, Viral/virology , SARS-CoV-2 , Skin Diseases/immunology , Societies, Medical/standards , Symptom Flare UpABSTRACT
BACKGROUND: Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; COVID-19), which causes coronavirus disease 2019, is highly contagious and a particularly popular problem in all around the world and also in all departments of every hospital. AIMS: Protecting the well-being of the aesthetic dermatologists while providing a sufficient workforce is vital for pandemic planning. RESULTS AND CONCLUSIONS: In this article, we will discuss this problem from an aesthetic dermatology aspect and we will review whether these procedures are safe or not.